Last reviewed · How we verify
Tetracyclin ointment
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation and bacterial growth.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Topical treatment of bacterial skin infections, Wound infection prevention, Superficial skin and soft tissue infections.
At a glance
| Generic name | Tetracyclin ointment |
|---|---|
| Also known as | Amoxicillin, Esomeprazole, Bismuth, marsupialization procedure |
| Sponsor | University of Oslo |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Tetracyclines are broad-spectrum antibiotics that work by reversibly binding to the bacterial 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosome. This inhibits protein synthesis and leads to bacteriostatic effects against a wide range of gram-positive and gram-negative bacteria. When formulated as an ointment, tetracycline is applied topically to treat localized bacterial skin infections and prevent infection in wounds.
Approved indications
- Topical treatment of bacterial skin infections
- Wound infection prevention
- Superficial skin and soft tissue infections
Common side effects
- Local skin irritation
- Contact dermatitis
- Photosensitivity (systemic form)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |